Table 1.
Descriptive statistics of analytic cohort 1
| Overall Analytic Cohort 1 (n = 206,036) | CKD Identified from lab data only (n = 181,750) |
CKD Identified from lab + Diagnosis (n = 24,286) | |
|---|---|---|---|
| Stage of CKD identified in lab data (N, %)a | |||
| Stage 1 | 612 (0.3%) | 549 (0.3%) | 63 (0.3%) |
| Stage 2 | 115,817 (56.2%) | 112,809 (62.1%) | 3008 (12.4%) |
| Stage 3 | 79,649 (38.7%) | 64,460 (35.5%) | 15,189 (62.5%) |
| Stage 4 | 9152 (4.4%) | 3793 (2.1%) | 5359 (22.1%) |
| Stage 5 | 806 (0.4%) | 139 (0.1%) | 667 (2.8%) |
| Age (Mean, SD) | 74.3 (9.1%) | 74.3 (9.0%) | 74.4 (9.5%) |
| Age Group (N, %) | |||
| Age < 65 | 17,397 (8.4%) | 14,920 (8.2%) | 2477 (10.2%) |
| Age 65–69 | 40,481 (19.7%) | 36,332 (20.0%) | 4149 (17.1%) |
| Age 70–74 | 49,365 (24.0%) | 43,996 (24.2%) | 5369 (22.1%) |
| Age 75–79 | 40,546 (19.7%) | 35,619 (19.6%) | 4927 (20.3%) |
| Age 80+ | 58,247 (28.3%) | 50,883 (28.0%) | 7364 (30.3%) |
| Gender (N, %) | |||
| Female | 129,424 (62.8%) | 116,011 (63.8%) | 13,413 (55.2%) |
| Male | 76,612 (37.2%) | 65,739 (36.2%) | 10,873 (44.8%) |
| Race/Ethnicity (N, %) | |||
| Hispanic | 7005 (3.4%) | 6074 (3.3%) | 931 (3.8%) |
| Non-Hispanic white | 170,259 (82.6%) | 152,192 (83.7%) | 18,067 (74.4%) |
| Non-Hispanic black | 24,153 (11.7%) | 19,358 (10.7%) | 4795 (19.7%) |
| Others | 4619 (2.2%) | 4126 (2.3%) | 493 (2.0%) |
| Original Reason for Medicare Eligibility (N, %) | |||
| Age | 188,585 (91.5%) | 166,783 (91.8%) | 21,802 (89.8%) |
| Disability | 17,451 (8.5%) | 14,987 (8.2%) | 2484 (10.2%) |
| Medicaid Enrolled (N, %) | |||
| No | 176,158 (85.5%) | 156,172 (85.9%) | 19,986 (82.3%) |
| Yes | 29,878 (14.5%) | 25,578 (14.1%) | 4300 (17.7%) |
| Geographic Location (N, %) | |||
| Large Central Metro | 25,785 (12.5%) | 22,856 (12.6%) | 2929 (12.1%) |
| Large Fringe Metro | 75,775 (36.8%) | 66,437 (36.6%) | 9338 (38.5%) |
| Medium Metro | 41,155 (20.0%) | 36,171 (19.9%) | 4984 (20.5%) |
| Small Metro | 21,118 (10.3%) | 18,664 (10.3%) | 2454 (10.1%) |
| Micropolitan | 20,055 (9.7%) | 17,460 (9.6%) | 2595 (10.7%) |
| Non-core area | 22,148 (10.8%) | 20,162 (11.1%) | 1986 (8.2%) |
| Chronic Conditions in 2010 (N, %) | |||
| 0–1 | 11,814 (5.7%) | 11,283 (6.2%) | 531 (2.2%) |
| 2–3 | 53,676 (26.1%) | 49,853 (27.4%) | 3823 (15.7%) |
| 4–5 | 74,894 (36.4%) | 66,607 (36.7%) | 8287 (34.1%) |
| 6+ | 65,652 (31.9%) | 54,007 (29.7%) | 11,645 (48.0%) |
| Outpatient Visits in 2010 (N, %) | |||
| 0–6 | 63,580 (30.9%) | 59,705 (32.9%) | 3875 (15.9%) |
| 7–11 | 57,634 (28.0%) | 40,993 (22.6%) | 6902 (28.4%) |
| 12–18 | 47,895 (23.3%) | 29,501 (16.2%) | 7426 (30.6%) |
| 19+ | 36,927 (17.9%) | 51,551 (28.4%) | 6083 (25.1%) |
| Saw Nephrologist in 2010 (N, %) | 18,995 (9.2%) | 5980 (3.3%) | 13,015 (53.6%) |
a CKD Stages: Stage 1 = estimated glomerular filtration rate (eGFR) ≥90 ml/min/1.73m2 and urine albumin-to-creatinine ratio (UACR) ≥30 mg/g; Stage 2 = eGFR 60–89; Stage 3 = eGFR 30–59; Stage 4 = eGFR 15–29; Stage 5 = eGFR < 15